

**Supplementary Table 4.** Baseline characteristics of patients who did not administer any lipid-lowering agents at baseline and during the study period

Characteristics	Total (n=3,499)	TAF (n=738)	TDF (n=2,761)	P-value
<b>Demographic characteristics</b>				
Age (yr)	49.9 (41.3–57.0)	49.1 (41.0–57.2)	50.0 (41.0–57.2)	0.904
Male, n (%)	2,125 (60.7)	401 (54.3)	1,724 (62.4)	<0.001
Height (cm)	166.8 (160.0–172.8)	167.1 (160.0–173.1)	166.8 (160.0–172.8)	0.522
Weight (kg)	65.7 (57.3–74.3)	66.1 (57.0–75.5)	65.5 (57.6–74.0)	0.456
Body mass index (kg/m <sup>2</sup> )	23.9 (21.8–26.1)	23.9 (21.9–26.1)	23.9 (21.8–26.1)	0.584
Systolic BP (mmHg)	121.5 (110.0–134.0)	126.0 (115.0–138.0)	120.0 (108.0–133.0)	<0.001
Diastolic BP (mmHg)	73.0 (66.0–81.0)	76.0 (69.0–83.0)	72.0 (65.0–80.0)	<0.001
Smoking status, n (%)				0.019
Never smoker	1,593 (45.5)	366 (49.6)	1,227 (44.4)	
Current smoker	634 (18.1)	126 (17.1)	508 (18.4)	
Past smoker	499 (14.3)	83 (11.2)	416 (15.1)	
Not available	773 (22.1)	163 (22.1)	610 (22.1)	
<b>Comorbidities</b>				
Diabetes, n (%)	220 (6.3)	47 (6.4)	173 (6.3)	0.987
Hypertension, n (%)	373 (10.7)	82 (11.1)	291 (10.5)	0.704
Stroke, n (%)	10 (0.3)	0 (0.0)	10 (0.3)	0.212
Myocardial infarction, n (%)	3 (0.1)	0 (0.0)	3 (0.1)	0.851
Heart failure, n (%)	9 (0.3)	2 (0.3)	7 (0.3)	0.999
Coronary artery disease, n (%)	18 (0.5)	4 (0.5)	14 (0.5)	0.999
Cirrhosis, n (%)	1,464 (41.8)	267 (36.2)	1,197 (43.4)	0.001
Fatty liver, n (%)	497 (14.2)	156 (21.1)	341 (12.4)	<0.001
HCC, n (%)	243 (6.9)	11 (1.5)	232 (8.4)	<0.001
<b>Laboratory findings</b>				
Platelets (×10 <sup>3</sup> /μL)	165.0 (118.0–209.0)	175.0 (140.0–216.0)	162.0 (111.0–207.0)	<0.001
AST (IU/L)	55.0 (35.0–92.0)	52.0 (34.0–90.0)	56.0 (35.0–92.0)	0.276
ALT (IU/L)	56.0 (30.0–120.0)	64.0 (32.0–122.0)	55.0 (30.0–120.0)	0.237
Prothrombin time, INR	1.1 (1.0–1.2)	1.0 (1.0–1.1)	1.1 (1.0–1.2)	<0.001
Albumin (g/dL)	3.9 (3.5–4.1)	3.9 (3.7–4.1)	3.9 (3.5–4.2)	0.391
Total bilirubin (mg/dL)	0.8 (0.6–1.1)	0.7 (0.6–0.9)	0.8 (0.6–1.2)	<0.001
Creatinine (mg/dL)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.8 (0.7–0.9)	0.555
eGFR (mL/min/1.73m <sup>2</sup> )	102.0 (93.0–110.0)	101.0 (93.0–109.0)	102.0 (94.0–111.0)	0.016
Total cholesterol (mg/dL)	169.0 (146.0–193.0)	182.0 (162.0–204.0)	165.0 (142.0–190.0)	<0.001
HDL (mg/dL)	51.0 (42.0–61.0)	56.0 (46.0–65.0)	50.0 (40.0–59.0)	<0.001
LDL (mg/dL)	109.0 (87.0–131.0)	116.0 (100.0–134.0)	104.0 (80.0–130.0)	<0.001
Triglyceride (mg/dL)	84.0 (67.0–113.0)	87.0 (70.0–115.0)	83.0 (66.0–111.0)	0.029
HBeAg-positive, n (%)	1,491 (47.6)	312 (44.1)	1,179 (48.6)	0.036
HBV DNA (log <sub>10</sub> IU/mL)	5.5 (3.2–7.0)	5.5 (3.8–7.1)	5.5 (3.0–7.0)	0.003

Data are presented as a frequency and proportion or as a mean value with interquartile range.

TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.